# A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

> **NCT05335993** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CanariaBio Inc.** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Ovarian Cancer
- Recurrent Epithelial Cancer of Ovary
- Recurrent Epithelial Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Peritoneal Cancer
- Recurrent Carcinoma of Ovary
- Adenocarcinoma of Ovary

## Interventions

- **BIOLOGICAL:** Oregovomab
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05335993
- **Lead sponsor:** CanariaBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-25
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335993, "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05335993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*